Working… Menu
Trial record 1 of 1 for:    swog s1418
Previous Study | Return to List | Next Study

Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT02954874
Recruitment Status : Recruiting
First Posted : November 4, 2016
Last Update Posted : April 20, 2021
Information provided by (Responsible Party):
National Cancer Institute (NCI)

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : May 31, 2026
Study Completion Date : No date given